maphere
Sep 25, 2:26 PM
$RGNX Check out the slide deck:
Per ChatGPT:
At the pivotal sura-vec dose, 6/10 evaluable patients were ≥2-step DRSS improved at Year 3 with no vision-threatening event and ZERO additional DR injections.
Of those 6:
• 2 maintained ≥2-step improvement from Yr 1
• 3 went from 1-step → 2-step improvement
• 1 went from no improvement → 2-step improvement
All after a single in-office injection 3 years earlier.
Small Phase 2 dataset, but that's a very interesting durability trajectory as
$ABBV advances NAAVIGATE.
The surprising finding is that several patients didn't merely maintain an early response—their DRSS category continued improving between Years 1 and 3 without rescue treatment.
And given that we've been following sura-vec closely, Slide 9 is probably the single ALTITUDE slide I'd save. It tells the story considerably better than the PR does.
https://www.regenxbio.com/science-innovation/publications/
0 replies
